Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTL NASDAQ:FTLF NASDAQ:MNPR NASDAQ:OCGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.56$1.57$1.18▼$2.70$415.20M2.021.54 million shs1.02 million shsFTLFFitLife Brands$11.01-4.9%$9.85$8.67▼$20.98$108.75M0.0228,820 shs20,987 shsMNPRMonopar Therapeutics$59.77+1.1%$58.62$29.18▼$105.00$395.88M1.52143,846 shs154,407 shsOCGNOcugen$1.21-0.8%$1.54$0.90▼$2.73$413M2.194.96 million shs3.73 million shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics+5.41%-6.02%-2.50%+8.33%-30.36%FTLFFitLife Brands+7.82%+16.50%+21.89%-16.15%-16.57%MNPRMonopar Therapeutics-0.54%-0.86%-3.67%-2.09%+70.56%OCGNOcugen+2.52%-10.95%-17.01%-50.81%+5.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.56$1.57$1.18▼$2.70$415.20M2.021.54 million shs1.02 million shsFTLFFitLife Brands$11.01-4.9%$9.85$8.67▼$20.98$108.75M0.0228,820 shs20,987 shsMNPRMonopar Therapeutics$59.77+1.1%$58.62$29.18▼$105.00$395.88M1.52143,846 shs154,407 shsOCGNOcugen$1.21-0.8%$1.54$0.90▼$2.73$413M2.194.96 million shs3.73 million shsMissed the SpaceX IPO? Buy These 7 Stocks InsteadThe space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics+5.41%-6.02%-2.50%+8.33%-30.36%FTLFFitLife Brands+7.82%+16.50%+21.89%-16.15%-16.57%MNPRMonopar Therapeutics-0.54%-0.86%-3.67%-2.09%+70.56%OCGNOcugen+2.52%-10.95%-17.01%-50.81%+5.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 2.89Moderate Buy$8.75460.90% UpsideFTLFFitLife Brands 2.25Hold$21.5095.28% UpsideMNPRMonopar Therapeutics 3.00Buy$107.9180.54% UpsideOCGNOcugen 2.60Moderate Buy$9.50685.12% UpsideCurrent Analyst Ratings BreakdownLatest FTLF, OCGN, MNPR, and AUTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026FTLFFitLife Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)6/2/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/2/2026MNPRMonopar Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$105.006/2/2026MNPRMonopar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/27/2026OCGNOcugen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $11.005/18/2026OCGNOcugen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026AUTLAutolus Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.004/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026MNPRMonopar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$75.39M5.51N/AN/A$0.67 per share2.33FTLFFitLife Brands$81.46M1.27$1.11 per share9.93$4.65 per share2.37MNPRMonopar TherapeuticsN/AN/AN/AN/A$20.62 per shareN/AOCGNOcugen$4.41M92.88N/AN/A($0.04) per share-30.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$287.53M-$1.09N/AN/AN/A-311.98%-128.59%-46.25%8/11/2026 (Estimated)FTLFFitLife Brands$6.33M$0.6018.239.57N/A6.64%18.31%8.21%N/AMNPRMonopar Therapeutics-$13.72M-$1.90N/AN/AN/AN/A-12.84%-12.57%8/11/2026 (Estimated)OCGNOcugen-$67.85M-$0.24N/AN/AN/A-1,192.18%-127,987.80%-135.48%7/30/2026 (Estimated)Latest FTLF, OCGN, MNPR, and AUTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026AUTLAutolus Therapeutics-$0.29-$0.27+$0.02-$0.27$26.27 million$26.22 million5/14/2026Q1 2026FTLFFitLife Brands$0.14$0.17+$0.03$0.17N/A$25.33 million5/14/2026Q1 2026MNPRMonopar Therapeutics-$0.8703-$0.46+$0.4103-$0.46N/AN/A5/5/2026Q1 2026OCGNOcugen-$0.05-$0.06-$0.01-$0.06$0.42 million$1.53 million3/27/2026Q4 2025AUTLAutolus Therapeutics-$0.27-$0.34-$0.07-$0.34$23.92 million$24.29 million3/27/2026Q4 2025MNPRMonopar Therapeutics-$0.5123-$0.61-$0.0977-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AOCGNOcugenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A5.805.28FTLFFitLife Brands0.781.520.49MNPRMonopar TherapeuticsN/A56.0456.04OCGNOcugen4.171.861.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%FTLFFitLife Brands2.32%MNPRMonopar Therapeutics1.83%OCGNOcugen10.27%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%FTLFFitLife Brands61.40%MNPRMonopar Therapeutics20.50%OCGNOcugen3.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.16 million197.75 millionOptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableMNPRMonopar Therapeutics106.70 million5.33 millionNot OptionableOCGNOcugen80338.52 million325.15 millionOptionableFTLF, OCGN, MNPR, and AUTL HeadlinesRecent News About These CompaniesHow The Ocugen (OCGN) Investment Story Is Evolving Without New Analyst GuidanceJune 5, 2026 | finance.yahoo.comWhy Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?June 4, 2026 | finance.yahoo.comWhy Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?June 4, 2026 | zacks.comOcugen Consolidates Financial Leadership Under New Accounting OfficerJune 3, 2026 | tipranks.comOcugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage CareJune 3, 2026 | zacks.comIs OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?June 3, 2026 | zacks.comOCGN's Catalyst Calendar for Trial Data and Filings Through 2028June 3, 2026 | zacks.comOcugen to Participate in Upcoming June Investor and Industry ConferencesJune 2, 2026 | finance.yahoo.comOcugen to Participate in Upcoming June Investor and Industry ConferencesJune 2, 2026 | globenewswire.comOcugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exitMay 26, 2026 | msn.comOcugen Announces Interim Chief Medical Officer Appointment TransitionMay 14, 2026 | tipranks.comOcugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior NotesMay 14, 2026 | finance.yahoo.comOcugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior NotesMay 14, 2026 | globenewswire.com3 Reasons Not to Buy Into the Hantavirus-Related Biotech RallyMay 13, 2026 | fool.comHC Wainwright Has Negative Forecast for Ocugen Q2 EarningsMay 13, 2026 | marketbeat.comOcugen (OCGN) Reports Q1 EPSMay 13, 2026 | finance.yahoo.comOcugen to Participate in Upcoming May Scientific and Investor ConferencesMay 13, 2026 | finance.yahoo.comOcugen, Inc. to Present Innovative Modifier Gene Therapy Platform at May 2026 ConferencesMay 13, 2026 | quiverquant.comQOcugen to Participate in Upcoming May Scientific and Investor ConferencesMay 13, 2026 | markets.businessinsider.comOcugen to Participate in Upcoming May Scientific and Investor ConferencesMay 13, 2026 | globenewswire.comOcugen (OCGN) Reports Q1 EPSMay 13, 2026 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFTLF, OCGN, MNPR, and AUTL Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.56 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.59 +0.03 (+1.92%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.FitLife Brands NASDAQ:FTLF$11.01 -0.57 (-4.92%) Closing price 04:00 PM EasternExtended Trading$10.76 -0.25 (-2.26%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Monopar Therapeutics NASDAQ:MNPR$59.77 +0.67 (+1.13%) Closing price 04:00 PM EasternExtended Trading$59.68 -0.09 (-0.15%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Ocugen NASDAQ:OCGN$1.21 -0.01 (-0.82%) Closing price 04:00 PM EasternExtended Trading$1.20 0.00 (-0.41%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
